ArticleInfluenza and other respiratory viruses2026
Antigenic Variation and Immune Recognition Inference From the COVID-19 Pandemic: An In Silico Comparative Analysis of Spike T Cell Epitopes From the SARS-CoV-2 Variants of Concern.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundWith increased transmission but reduced disease severity, the Omicron SARS-CoV-2 variants have contributed to the multifaceted transition of COVID-19 from a global pandemic to an endemic disease. Nonetheless, the persistence of hypermutable viral variants and their ability to infect both vaccinated and previously infected individuals raise concerns about continued viral evolution and immune evasion.
methodsThis study employs comprehensive in silico analyses to compare the five former variants of concern (VOCs) to elucidate their T cell antigenic variations in relation to human leukocyte antigen (HLA) recognition and binding.
resultsOur major histocompatibility complex (MHC) class I and II epitope predictions suggest that the Omicron BA.1 variant harbors more putative epitopes than other VOCs (2.0-11.0 times more). Moreover, the distribution of predicted MHC-II epitopes across HLA alleles differs substantially, with Omicron displaying significant differences from at least three VOCs in all analyses. Investigation of HLA-epitope binding affinities indicates that Omicron epitopes often exhibit enhanced HLA binding compared with the Wuhan Reference (57.8%, 81.8%, and 60.0% of MHC-I, MHC-II regular, and MHC-II promiscuous pairs, respectively), which could influence immune responses.
conclusionsThese findings reveal marked differences in the putative epitope profiles of Omicron BA.1 and the Wuhan Reference, as well as other pre-Omicron VOCs, highlighting its altered HLA recognition status. Given the continued transmission and emergence of new SARS-CoV-2 lineages, this study highlights the importance of ongoing research to understand the evolutionary dynamics of high-risk SARS-CoV-2 variants, their host immune system interactions, and the downstream implications in vaccine and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.